NV-GSMA
The smartphone will remain the dominant consumer device into the new decade, but the arrival of 5G will not guarantee a surge in device upgrades, according to new GSMA Intelligence research. A new report, The Future of Devices , published at the Consumer Electronics Show (CES) 2020 in Las Vegas today, provides a wealth of insight on consumer technology adoption trends over the coming years, including the outlook for smartphones, smart speakers, wearables and other emerging categories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005796/en/
Based on the results of GSMA Intelligence’s 2019 Consumer Survey, the report found that smartphone ownership among adults in most high- and middle-income countries is at 85-95 per cent. However, only 30-40 per cent of survey respondents in significant markets such as the US, Europe and Australia said the arrival of 5G is likely to result in a smartphone upgrade in the short term. By contrast, markets such as China and South Korea will be early adopters; nearly 50 per cent of Chinese consumers say they will buy a 5G phone as soon as they are available.
“The device ecosystem will be critical in shaping the trajectory of 5G adoption,” said Peter Jarich, Head of GSMA Intelligence. “However, it’s a mistake to believe that consumers in every market will look at 5G upgrades in the same way. Operators and device manufacturers will need to understand consumer demand on a granular level if they hope to make the most of the 5G opportunity.”
5G
Mixed picture for smart home and wearables
Fragmentation and a lack of compatibility between manufacturers hamper the adoption of smart home devices. However, this segment is being boosted by the growing popularity of smart speakers, such as Amazon’s Echo devices, which are increasingly acting as a single control point within the home. Smart speakers were the fastest moving category in the 2019 survey, now owned by 21 per cent of households, up ten percentage points over the previous year. Speakers have become a key battleground in the broader development of AI. Amazon and Google are furthest ahead, but both face the challenge of getting customers to go beyond basic functionality to higher-value tasks such as purchasing goods.
Meanwhile, the adoption rates for fitness trackers and smartwatches also picked up in 2019, and are now owned by 21 per cent and 10 per cent of adults, respectively. Millennials show the most substantial ownership rates of these devices, being more tech-savvy than older generations and also benefitting from an employer or insurance-based subsidies. However, the report notes that connected health devices continue to be sorely underrepresented among older populations. Missing older people is a missed opportunity for tech companies and governments, given that such devices can facilitate remote monitoring for a range of conditions, reducing the volume of in-person consultations and the strain on national healthcare systems.
The 2020 edition of The Future of Devices report is available to accredited members of the press on request. This report is based on GSMA Intelligence’s 2019 Consumer Survey, which surveyed 38,000 respondents across 36 key markets, using a blend of online and face-to-face sampling methodologies.
GSMA Intelligence @ #CES2020
GSMA Intelligence will be hosting a seminar dedicated to IoT at the MGM Grand in Las Vegas during CES. During this session, GSMA Intelligence will feature its latest forecasts and expectations for both consumer and enterprise IoT.
Our senior analysts will be available on-site for one-to-one media interviews during the week. We can provide expert commentary across a range of industry topics and discuss all the key announcements and developments. Please contact us at: media@gsmaintelligence.com
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005796/en/
Contact:
For the GSMA: GSMA Press Office Isobel Moseley pressoffice@gsma.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
